Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China’s recently introduced QCE system is first of a kind for multin…
Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China’s recently introduced QCE system is first of a kind for multin…
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumorsPer licence agreement, EirGenix, Inc is responsible for development and manufacturing; …
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumorsPer licence agreement, EirGenix, Inc is responsible for development and manufacturing; …
Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:Cosentyx was USD 791 million, +41% (c…
Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:Cosentyx was USD 791 million, +41% (c…
Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European marketsRizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medi…
Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European marketsRizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medi…
Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one of the most serious side effects of chemotherapy, hospitalizing …
Richard Francis, CEO Sandoz, to step down on March 31, 2019Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 – Novartis announced today that Richard Francis will be stepping down as CEO of Sandoz, …